Skip to main navigation Skip to search Skip to main content

Efficacy of cannabinoids in pharmacoresistant epilepsy: A narrative review of the literature

  • Alexandra Ferreiros
  • , Elkin Beltrán-Carrascal
  • , Paula Restrepo
  • , Camila Pantoja
  • , Camilo Castañeda-Cardona
  • , Pieralessandro Lasalvia
  • , Laura Van Der Werf
  • , Daniel Nariño
  • , Diego Rosselli

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Epilepsy is a common neurological disorder that affects approximately 1% of the world’s pop7u-lation. About one third of those patients suffer from treatment-resistant epilepsy (TRE8), defined as failure to stop seizures despite adequate trials of at least two medications at therapeutic dosa-ges. There has been a growing interest in the development of novel antiepileptic drugs with different mechanisms of action. This narrative review, based on 42 references retrieved from Scopus and Medline, discusses the scientific data from human and animal studies regarding the efficacy of cannabis-based treatment for epilepsy. Benefits have been described in pre-clinical and clinical studies in children, but ongoing research will clarify the real role of cannabinoids in TRE.

Translated title of the contributionEficacia de los canabinoides en epilepsia refractaria: Una revisión narrativa de la literatura
Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalIatreia
Volume33
Issue number2
DOIs
StatePublished - 01 Apr 2020

Keywords

  • Cannabis
  • Drug Resistant Epilepsy
  • Review

Fingerprint

Dive into the research topics of 'Efficacy of cannabinoids in pharmacoresistant epilepsy: A narrative review of the literature'. Together they form a unique fingerprint.

Cite this